Candel Therapeutics Stock Soars 150% After Groundbreaking Prostate Cancer Trial Results

On Wednesday, shares of Candel Therapeutics, Inc. (NASDAQ: CADL) saw a remarkable surge, skyrocketing by 150%. This surge followed the release of encouraging outcomes from a pivotal phase 3 clinical trial evaluating their innovative CAN-2409 viral immunotherapy. This therapy, when used alongside radiation treatment, targets localized prostate cancer in patients classified as intermediate to high risk.

The trial, which followed a Special Protocol Assessment from the FDA, saw the participation of 745 individuals, all assessing the efficacy of CAN-2409. Impressively, the therapy achieved its primary endpoint, reporting a statistically significant improvement in clinical outcomes. Notably, patients treated with CAN-2409 combined with standard care experienced better disease-free survival rates compared to those receiving only standard care.
Candel's CAN-2409 aims to stimulate a specific immune reaction against tumors, promoting what’s known as immunogenic cell death, which is anticipated to work synergistically with radiation therapy. This innovation comes at a crucial time, with more than 100,000 new localized prostate cancer diagnoses persistently occurring in the United States each year, and a glaring absence of significant advancements in treatments over the past twenty years. The market potential for such breakthroughs could exceed $10 billion.

The trial's findings are compelling, highlighting a 14.5% relative improvement in disease-free survival at 54 months for the treatment cohort. Additionally, there was an increase in the number of patients achieving low prostate-specific antigen (PSA) levels and a rise in rates for pathological complete responses observed in post-treatment biopsies. With a median follow-up duration of 50.3 months, key measures focused on evaluating tumor recurrence through post-treatment biopsies.
Furthermore, Candel presented phase 2 trial results for CAN-2409 as a standalone treatment, demonstrating enhancements in the time until radical treatment was required, as well as a higher percentage of patients with negative biopsy results. However, these outcomes did not reach statistical significance, although the safety profile remained consistent with the phase 3 trial.

Looking ahead, Candel is strategizing to meet with the FDA to discuss the potential regulatory path for CAN-2409, aiming for the approval of this promising therapeutic option. In addition, the company plans to unveil detailed trial data at upcoming medical conferences, which could generate further excitement in the market. For stock traders eyeing biotech opportunities, Candel’s recent performance might represent a pivotal point in a promising journey toward advancing prostate cancer treatment.